Literature DB >> 17727670

Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST document E.DEF 8.1)--report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).

F Drobniewski1, S Rüsch-Gerdes, S Hoffner.   

Abstract

This review describes the methods available for drug susceptibility testing of Mycobacterium tuberculosis. The methods have been developed over several decades and are restricted to specialised centres in most European countries, as they are technically demanding, require appropriate isolation facilities and can be difficult to interpret. The absolute concentration, resistance ratio and proportion methods can all give accurate results, provided that they are carefully quality-controlled and standardised. Automated rapid culture and molecular methods have been evaluated at large reference centres and in multicentre collaborations, and perform well for testing susceptibility to most first- and second-line anti-tuberculosis drugs. Accuracy is more important than rapid testing, and this is most reliably achieved if drug susceptibility tests are done in a small number of well-equipped, experienced laboratories that participate and perform well in an international drug susceptibility testing quality assessment scheme. The WHO Supranational Laboratory Quality Control Network offers a global scheme that assesses the ability of participating laboratories to identify isoniazid, rifampicin, ethambutol and streptomycin resistance. Second-line drug resistance testing is currently being standardised, and such testing should only be performed at the national reference laboratories in western and central European countries because of the relatively small number of cases and the concomitant difficulty of maintaining testing proficiency in multiple centres performing small numbers of tests. There is a need to expand international external quality assessment to include second-line drug susceptibility testing.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17727670     DOI: 10.1111/j.1469-0691.2007.01813.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  8 in total

1.  Genetic Diversity of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis Isolates in the Capital of Iran, Revealed by Whole-Genome Sequencing.

Authors:  Farzam Vaziri; Thomas A Kohl; Hasan Ghajavand; Mansour Kargarpour Kamakoli; Matthias Merker; Shima Hadifar; Sharareh Khanipour; Abolfazl Fateh; Morteza Masoumi; Seyed Davar Siadat; Stefan Niemann
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

2.  GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples.

Authors:  A Lacoma; N Garcia-Sierra; C Prat; J Ruiz-Manzano; L Haba; S Rosés; J Maldonado; J Domínguez
Journal:  J Clin Microbiol       Date:  2008-09-10       Impact factor: 5.948

3.  Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China.

Authors:  Peng Xu; Xia Li; Ming Zhao; Xiaohong Gui; Kathryn DeRiemer; Sebastien Gagneux; Jian Mei; Qian Gao
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

4.  Can immune parameters be used as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis?

Authors:  Bayram Kiran; Tulin Cagatay; Philip Clark; Filiz Kosar; Penbe Cagatay; Sibel Yurt; Faruk Suzergoz; Ali Osman Gurol
Journal:  Arch Med Sci       Date:  2010-03-09       Impact factor: 3.318

5.  Correlation between the BACTEC MGIT 960 culture system with Genotype MTBDRplus and TB-SPRINT in multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil.

Authors:  Nayanne Gama Teixeira Dantas; Phillip Noel Suffys; Wânia da Silva Carvalho; Harrison Magdinier Gomes; Isabela Neves de Almeida; Lida Jouca de Assis Figueiredo; Alan Douglas Gonçalves; Michel Kireopori Gomgnimbou; Guislaine Refregier; Christophe Sola; Silvana Spíndola de Miranda
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-11       Impact factor: 2.743

Review 6.  Mycobacteriosis and Tuberculosis: Laboratory Diagnosis.

Authors:  Davood Azadi; Tahereh Motallebirad; Kazem Ghaffari; Hasan Shojaei
Journal:  Open Microbiol J       Date:  2018-03-30

7.  First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017.

Authors:  Saskia Glasauer; Doris Altmann; Barbara Hauer; Bonita Brodhun; Walter Haas; Nita Perumal
Journal:  PLoS One       Date:  2019-06-12       Impact factor: 3.240

8.  Evaluation of a microcolony growth monitoring method for the rapid determination of ethambutol resistance in Mycobacterium tuberculosis.

Authors:  Alice L den Hertog; Sandra Menting; Ernst T Smienk; Jim Werngren; Sven Hoffner; Richard M Anthony
Journal:  BMC Infect Dis       Date:  2014-07-10       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.